News2020-02-23T23:18:18-05:00
Page-TitleNEWS

Virpax Pharmaceuticals Announces Appointment of Christopher M. Chipman, Chief Financial Officer

Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the appointment of Christopher M. Chipman, CPA, Chief Financial Officer. “As Chairman of the Audit Committee, it is with great pleasure that I welcome Chris [...]

June 2nd, 2020|Press Release|

Virpax Pharmaceuticals Strengthens Board of Directors with Appointment of Gary S. Jacob, Ph.D. to its Board

Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the appointment of Gary S. Jacob, Ph.D. to its Board of Directors.“We are pleased to welcome Dr. Jacob as a new independent director to [...]

April 28th, 2020|Press Release|

Virpax Pharmaceuticals Licenses Liposome Drug Delivery Technology From LipoCure

Virpax to Develop a Long-Acting Liposomal Gel (Lipogel) for Post-Operative Pain Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with LipoCure to develop pain management products using its liposome drug delivery technology. [...]

June 4th, 2018|Press Release|

Virpax Pharmaceuticals Licenses ‘Patch-in-a-Can’ MedSpray® Technology From MedPharm Ltd

Transdermal Delivery Technology Integrated Into DSF100 NSAID Spray Film 1.3% Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with MedPharm Ltd, a leading contract provider of topical and transdermal product design and [...]

May 29th, 2018|Press Release|
Go to Top